Hydroxychloroquine, Drugs Monitor, Page 3

(01 Dec 2020) Hydroxychloroquine- HCQ+/-AZT does not facilitate virologic cure

December 5, 2020

Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19 https://doi.org/10.1016/j.eclinm.2020.100645 NCT04349592 study enrolled 456 participants (152 in each of three groups: HC+AZ, HC, placebo) between 13 April and 1 August 2020. HC+AZ, HC,… Continue reading "(01 Dec 2020) Hydroxychloroquine- HCQ+/-AZT does not facilitate virologic cure"

(29 Nov 2020) Hydroxychloroquine- Zinc supplements did not enhance the clinical efficacy of HCQ

November 30, 2020

Do Zinc Supplements Enhance the Clinical Efficacy of Hydroxychloroquine?: a Randomized, Multicenter Trial https://doi.org/10.1007/s12011-020-02512-1 This was a randomized clinical trial (NCT04447534) conducted at three major University hospitals in Egypt. One hundred ninety-one patients with a confirmed diagnosis of COVID-19 infection… Continue reading "(29 Nov 2020) Hydroxychloroquine- Zinc supplements did not enhance the clinical efficacy of HCQ"

(25 Nov 2020) Hydroxychloroquine- combination with AZT helpful in recovery

November 27, 2020

Assessment of COVID-19 Treatment containing both Hydroxychloroquine and Azithromycin: A Natural Clinical Trial https://doi.org/10.1111/ijcp.13856 The study included 161 patients who were admitted with positive RT-PCR and clinical symptoms of COVID-19. In terms of severity, 53 (32.9%) patients had mild condition,… Continue reading "(25 Nov 2020) Hydroxychloroquine- combination with AZT helpful in recovery"

(04 Nov 2020) Azithromycin, Nitazoxanide, Ivermectin and HCQ- AZT in combination with drugs proven beneficial

November 9, 2020

Early COVID-19 Therapy with Azithromycin Plus Nitazoxanide, Ivermectin or Hydroxychloroquine in Outpatient Settings Significantly Reduced Symptoms Compared to Known Outcomes in Untreated Patients https://www.medrxiv.org/content/10.1101/2020.10.31.20223883v1.full.pdf The objective of the present study (NCT04446429) was to elucidate whether the conduction of a full… Continue reading "(04 Nov 2020) Azithromycin, Nitazoxanide, Ivermectin and HCQ- AZT in combination with drugs proven beneficial"

(03 Nov 2020) Hydroxychloroquine- did not prevent severe outcomes or improved clinical scores

November 5, 2020

Treating COVID-19 With Hydroxychloroquine (TEACH): A Multicenter, Double-Blind Randomized Controlled Trial in Hospitalized Patients https://doi.org/10.1093/ofid/ofaa446 In a multicenter, double-blind randomized clinical trial (NCT04369742)of HCQ among patients hospitalized with laboratory-confirmed COVID-19, Subjects were randomized in a 1:1 ratio to HCQ or… Continue reading "(03 Nov 2020) Hydroxychloroquine- did not prevent severe outcomes or improved clinical scores"

(01 Nov 2020) Hydroxychloroquine, Lopinavir/R- no benefit in improving viral clearance

November 5, 2020

Comparison of antiviral effect for mild-to-moderate COVID-19 cases between lopinavir/ritonavir versus hydroxychloroquine: A nationwide propensity score-matched cohort study https://doi.org/10.1016/j.ijid.2020.10.062 In a nationwide retrospective study, 4,197 patients with mild-to-moderate COVID-19 were included. Patients were categorized into three groups: LPV/r (n =… Continue reading "(01 Nov 2020) Hydroxychloroquine, Lopinavir/R- no benefit in improving viral clearance"

(29 Oct 2020) Hydroxychloroquine- no benefit in viral load reduction

October 31, 2020

No benefit of hydroxychloroquine on SARS-CoV-2 viral load reduction in non-critical hospitalized patients with COVID-19 https://doi.org/10.1007/s42770-020-00395-x This prospective study comprised consecutive viral load measurements in patients with COVID-19 hospitalized with a moderate illness. Patients received 400 mg of HCQ every… Continue reading "(29 Oct 2020) Hydroxychloroquine- no benefit in viral load reduction"

(21 Oct 2020) Hydroxychloroquine- older patients with mild-to-moderate COVID-19 did not experience better clinical or virological outcomes

October 22, 2020

A placebo-controlled double blind trial of hydroxychloroquine in mild-to-moderate COVID-19 https://www.medrxiv.org/content/10.1101/2020.10.19.20214940v1 A multicentre randomized double-blind placebo-controlled trial ( NCT04325893) evaluating hydroxychloroquine in older COVID-19 patients was conducted . Eligible patients were randomized in a 1:1 ratio to receive either 800 mg… Continue reading "(21 Oct 2020) Hydroxychloroquine- older patients with mild-to-moderate COVID-19 did not experience better clinical or virological outcomes"

(18 Oct 2020) Hydroxychloroquine- No significant reduction in incidence of COVID 19 among health workers

October 22, 2020

Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1571/5929230 A randomized, double-blind, placebo-controlled clinical trial (NCT04328467) of healthcare workers with ongoing exposure to persons with SARS-CoV-2 was conducted. Participants across the United States and in the… Continue reading "(18 Oct 2020) Hydroxychloroquine- No significant reduction in incidence of COVID 19 among health workers"

(15 Oct 2020) Remdesivir, Hydroxychloroquine, Lopinavir and Interferon- Interim results from Solidarity trial suggests these have little or no effect on hospitalized COVID-19

October 17, 2020

Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results https://www.medrxiv.org/content/10.1101/2020.10.15.20209817v1 The interim results from Solidarity trials (ISRCTN83971151 , NCT04315948 ) are presented. In 405 hospitals in 30 countries 11,266 adults were randomized, with 2750 allocated Remdesivir, 954 Hydroxychloroquine, 1411 Lopinavir, 651 Interferon… Continue reading "(15 Oct 2020) Remdesivir, Hydroxychloroquine, Lopinavir and Interferon- Interim results from Solidarity trial suggests these have little or no effect on hospitalized COVID-19"

Tag: Hydroxychloroquine